AVENUE THERAPEUTICS, INC.
Close on Oct 16, 2026
- Market cap
- $1.42M
- P/E (TTM)
- –
- Dividend yield
- –
About Avenue Therapeutics
Pharmaceutical Preparations, SIC 2834
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic conditions. The company's primary product candidates include ATX-04, an orally administered selective beta-2 adrenergic agonist under development for the treatment of Pompe disease as an adjunct to enzyme replacement therapy, and intravenous tramadol, a Schedule IV opioid candidate designed for the management of postoperative acute pain in hospital or postsurgical settings. Avenue previously held rights to BAER-101 for epilepsy and panic disorders before divesting the program. Its prospective target end users are treating physicians, surgical practitioners, and patients suffering from rare lysosomal storage disorders or acute postsurgical pain.
The business operates as a majority-controlled subsidiary of Fortress Biotech, Inc. Its clinical and regulatory initiatives primarily target the United States and European healthcare markets, and the company holds worldwide licensing rights for ATX-04 as well as licensing rights to develop and commercialize intravenous tramadol. The provided report does not state the specific location of its corporate headquarters.
Summary of the business section of Avenue Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AVENUE THERAPEUTICS, INC.
- Headquarters
- Bay Harbor Islands, FL
- Address
- 1111 Kane Concourse, Suite 301 33154
- Phone
- (781) 652-4500
- Employees
- 1, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, New York, NY
Stock & identifiers
- Ticker
- ATXI
- Exchange
- OTC
- IPO date
- Jun 27, 2017
- Shares outstanding
- 3M, Aug 4, 2026
- Public float
- $571.90K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-75 reverse, Apr 26, 2024; 1-for-75 reverse, Mar 31, 2024; 1-for-15 reverse, Sep 23, 2022; 1-for-15 reverse, Sep 23, 2022; 1-for-3 reverse, Aug 11, 2017
- SEC CIK
- 1644963
- CUSIP
- 05360L403
- ISIN
- US05360L4032
- LEI
- 549300IN52C2XAYTBO53
- EIN
- 47-4113275
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Neil Herskowitz | Director | 97 |
| Jay D. Kranzler | Director | 559 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 PEO1 | $840.10K | $728.60K | $155.35K | $0 | – |
| FY2024 PEO2 | $0 | $0 | $155.35K | $0 | – |
| FY2024 PEO3 | $155.35K | $115.87K | $155.35K | $0 | – |
| FY2023 PEO1 | $1.21M | $659.20K | $260.00K | $0 | – |
| FY2023 PEO2 | $0 | $0 | $260.00K | $0 | – |
| FY2023 PEO3 | $0 | $0 | $260.00K | $0 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1 full-time employee.”
Corporate history
Events identified from SEC filings